Fortrea Holdings (FTRE) Depreciation & Amortization (CF) (2022 - 2026)
Fortrea Holdings (FTRE) posted Depreciation & Amortization (CF) of $19.8 million for Q1 2026, up 2.59% on a QoQ basis from $19.3 million in Q4 2025, and up 1.54% year-over-year from $19.5 million in Q1 2025.
Fortrea Holdings (FTRE) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Fortrea Holdings' Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $19.8 million for Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 1.54% year-over-year to $19.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $78.3 million (down 5.55% YoY) and the FY2025 annual result came in at $78.0 million, down 10.24% from the prior year.
- Depreciation & Amortization (CF) was $19.8 million for Q1 2026 at Fortrea Holdings, up from $19.3 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $25.1 million in Q2 2023 and bottomed at $19.3 million in Q4 2025.
- A 5-year average of $22.0 million and a median of $22.0 million in 2022 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) gained 8.37% — and 2025, when it decreased 17.02%.
- Fortrea Holdings' Depreciation & Amortization (CF) stood at $23.9 million in 2022, then gained by 2.09% to $24.4 million in 2023, then fell by 14.75% to $20.8 million in 2024, then retreated by 7.21% to $19.3 million in 2025, then gained by 2.59% to $19.8 million in 2026.
- Business Quant data shows FTRE's Depreciation & Amortization (CF) at $19.8 million in Q1 2026, $19.3 million in Q4 2025, and $19.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Fortrea Holdings | 1.83 Bn | 1.68 Bn | 123.60 Mn | 19.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.80 Mn |
| Mar 31, 2026 | 19.80 Mn |
| Dec 31, 2025 | 19.30 Mn |
| Dec 31, 2025 | 19.30 Mn |
| Sep 30, 2025 | 19.60 Mn |
| Sep 30, 2025 | 19.60 Mn |
| Jun 30, 2025 | 19.60 Mn |
| Jun 30, 2025 | 19.60 Mn |
| Mar 31, 2025 | 19.50 Mn |
| Mar 31, 2025 | 19.50 Mn |
| Dec 31, 2024 | 20.80 Mn |
| Dec 31, 2024 | 20.80 Mn |
| Sep 30, 2024 | 21.20 Mn |
| Sep 30, 2024 | 21.20 Mn |
| Jun 30, 2024 | 21.40 Mn |
| Jun 30, 2024 | 21.40 Mn |
| Mar 31, 2024 | 23.50 Mn |
| Mar 31, 2024 | 23.50 Mn |
| Dec 31, 2023 | 24.40 Mn |
| Dec 31, 2023 | 24.40 Mn |